Tucidinostat - Wikipedia
Tucidinostat (INN, also known as chidamide and sold under the brand names Epidaza and Hiyasta) is a histone deacetylase inhibitor (HDI) developed in China. [1] It was also known as HBI-8000. [2] It is a benzamide HDI and inhibits Class I HDAC1, HDAC2, HDAC3, as well as …
Therapeutic potential of tucidinostat, a subtype-selective HDAC ...
2022年9月22日 · Tucidinostat (formerly known as chidamide), a novel subtype-selective HDAC inhibitor, inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10. Tucidinostat is approved in relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL), advanced breast cancer and R/R adult T-cell leukemia-lymphoma (ATLL).
Tucidinostat Health Professional Drug Record | NIH - Clinicalinfo
2024年1月30日 · Investigational HIV drug information about tucidinostat for health professionals: pharmacology, clinical trials, adverse events, and more.
Clinical Outcomes of Tucidinostat Therapy for …
2023年11月2日 · 【Objective】 Tucidinostat, approved for relapsed/refractory adult T-cell leukemia-lymphoma (ATL) treatment in June 2021 in Japan, demonstrated an objective response rate (ORR) of 30.4%, progression-free survival (PFS) of 1.7 months (95% CI: 0.8-7.4), and overall survival (OS) of 7.9 months (95% CI: 2.3-18.0) in a phase IIb trial for 23 cases ...
Tucidinostat: Uses, Interactions, Mechanism of Action - DrugBank …
Chidamide is an orally bioavailable histone deacetylase (HDAC) inhibitor derived from the benzamide class. Histone deacetylase inhibitors are a class of cancer drugs that induce selective regulation of gene expression in cancer cells. [HUYA Biosciences Press Release]
Efficacy and safety of tucidinostat in patients with advanced …
Tucidinostat (previously known as chidamide) is an orally administered, subtype-selective inhibitor of histone deacetylase (HDAC). It specifically targets HDAC1, HDAC2, HDAC3, and HDAC10, resulting in epigenetic reprogramming and inhibiting the growth of various tumor types (13-16).
Tucidinostat | C22H19FN4O2 | CID 12136798 - PubChem
Tucidinostat is an orally bioavailable benzamide-type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with potential antineoplastic activity. Upon administration, tucidinostat binds to and inhibits HDACs, leading to an increase of acetylation levels of histone proteins.
Oral HDAC inhibitor tucidinostat in patients with relapsed or ...
2023年3月3日 · Tucidinostat (formerly known as chidamide) is an orally available, novel benzamide class of histone deacetylase (HDAC) inhibitor that selectively blocks class I and class IIb HDAC.
Clinical outcomes of tucidinostat-based therapy after prior …
Tucidinostat, a histone deacetylase (HDAC) inhibitor, induces cell cycle arrest, differentiation, and death in cancer cells by modifying the status of acetylation on histone and non-histone proteins and changes the tumor microenvironment to exert anti-tumor effects .
Tucidinostat Patient Drug Record | NIH - Clinicalinfo
2024年1月31日 · Tucidinostat is an investigational drug that is being studied as part of a strategy to cure HIV infection. Tucidinostat belongs to a group of HIV drugs called latency-reversing agents. 3.